Moderna — mFLUSIVA (mRNA-1010) $MRNA
for Prevention of seasonal influenza
FDA approves Moderna's mRNA influenza vaccine mFLUSIVA for the prevention of seasonal influenza in adults.
for Prevention of seasonal influenza
FDA approves Moderna's mRNA influenza vaccine mFLUSIVA for the prevention of seasonal influenza in adults.
Flu season is the yearly stretch of cold months when influenza outbreaks spread through a community, typically taking about two days after exposure for symptoms to appear and roughly three weeks to peak before fading. mFLUSIVA is an mRNA vaccine that delivers genetic instructions teaching the body's cells to make a piece of the influenza virus, so the immune system learns to recognize and attack it. Because that immune memory is built before exposure, the vaccine may help adults avoid getting sick when flu season arrives.
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
Source: ClinicalTrials.gov